Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PRNP | P04156 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL2184448 | 0.98 | GPR3 (0.61) | GPR3ALDH1A1CYP1A2HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL14775623 | 0.96 | GPR3 (0.59) | GPR3ALDH1A1CYP1A2HPGDHSD17B10 | |
| SCHEMBL27974035 | 0.88 | ALDH1A1 (0.56) | GPR3ALDH1A1CYP1A2HPGDHSD17B10 | |
| Formamide SCHEMBL28690144 | 0.87 | HSD17B10 (0.55) | GPR3ALDH1A1CYP1A2HPGDHSD17B10 | |
| SCHEMBL1772609 | 0.80 | L3MBTL1 (0.53) | GPR3ALDH1A1CYP1A2HPGDHSD17B10 | |
| SCHEMBL29461212 | 0.79 | TDP1 (0.54) | GPR3ALDH1A1CYP1A2HPGDHSD17B10 | |
| SCHEMBL856788 | 0.79 | TDP1 (0.54) | GPR3ALDH1A1CYP1A2HPGDHSD17B10 | |
| SCHEMBL85621 | 0.78 | GPR3 (1.00) | GPR3ALDH1A1CYP1A2HPGDHSD17B10 | |
| SCHEMBL18574483 | 0.77 | GPR3 (0.59) | GPR3ALDH1A1CYP1A2HPGDHSD17B10 | |
| SCHEMBL9388561 | 0.77 | GPR3 (0.59) | GPR3ALDH1A1CYP1A2HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 680 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4151218-A1 | LINAGLIPTIN, A XANTHINE DERIVATIVE AS DPP-4 INHIBITOR, FOR USE IN THE TREATMENT OF SIRS AND/OR SEPSIS | Boehringer Ingelheim International GmbH (DE) | 2023-03-22 | — | — | EP | claimed |
| US-20220184088-A1 | USES OF DPP IV INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-06-16 | — | — | US | claimed |
| EP-3939577-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2022-01-19 | — | — | EP | claimed |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2021-04-01 | — | — | US | claimed |
| US-20200222411-A1 | USES OF DPP IV INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-07-16 | — | — | US | claimed |
| EP-3626238-A1 | DPP-4 INHIBITORS FOR USE FOR THE TREATMENT OF WOUND HEALING IN DIABETIC PATIENTS | Boehringer Ingelheim International GmbH (DE) | 2020-03-25 | — | — | EP | claimed |
| US-20190202833-A1 | USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-04 | — | — | US | claimed |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2019-04-11 | — | — | US | claimed |
| EP-3029040-B1 | METHOD FOR PRODUCING CHIRAL 8-(3-AMINO-PIPERIDIN-1-YL) -XANTHINES | BOEHRINGER INGELHEIM INT (DE) | 2019-04-03 | — | — | EP | claimed |
| US-10202383-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-02-12 | — | — | US | claimed |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-16 | — | — | US | claimed |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-09 | — | — | US | claimed |
| US-7407955-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-08-05 | — | — | US | claimed |
| WO-2008017670-A1 | PYRROLO [3, 2 -D] PYRIMIDINES AS DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | claimed |
| US-20070281940-A1 | USES OF DPP-IV INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-06 | — | — | US | claimed |
| US-20060142310-A1 | for preventing or treating disorders connected with an increased DPP-IV activity, especially of diabetes mellitus type I or type II, prediabetes, or reduction of glucose tolerance; 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| CN-1749250-A | Chemical synthetic method for 2-chloro-4-amino-6,7-dimethoxy quinazoline | DIANHUA GROUP CO LTD HANGZHOU (CN) | 2006-03-22 | — | — | CN | claimed |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| US-20050187227-A1 | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-25 | — | — | US | claimed |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202383-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | GPR3 499/4885ALDH1A1 196/4885CYP1A2 294/4885 |
| US-20220184088-A1 | USES OF DPP IV INHIBITORS | DPP4, DPP3, DPP7 | GPR3 2485/4885ALDH1A1 648/4885CYP1A2 1187/4885 |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | GPR3 2874/4885ALDH1A1 412/4885CYP1A2 956/4885 |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | GPR3 522/4885ALDH1A1 213/4885CYP1A2 364/4885 |
| US-20060142310-A1 | for preventing or treating disorders connected with an increased DPP-IV activity, especially of diabetes mellitus type I or type II, prediabetes, or reduction of glucose tolerance; 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine | DPP4, DPP7, DPP8 | GPR3 1359/4885ALDH1A1 229/4885CYP1A2 262/4885 |
| US-20070281940-A1 | USES OF DPP-IV INHIBITORS | DPP4, DPP3, DPP7 | GPR3 2445/4885ALDH1A1 608/4885CYP1A2 1360/4885 |
| US-20200222411-A1 | USES OF DPP IV INHIBITORS | DPP4, DPP3, DPP7 | GPR3 2485/4885ALDH1A1 648/4885CYP1A2 1187/4885 |
| US-20190202833-A1 | USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS | DPP4, DPP3, DPP7 | GPR3 1114/4885ALDH1A1 2418/4885CYP1A2 2383/4885 |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | GPR3 522/4885ALDH1A1 213/4885CYP1A2 364/4885 |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | DPP8, DPP4, DPP7 | GPR3 542/4885ALDH1A1 287/4885CYP1A2 616/4885 |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | GPR3 2874/4885ALDH1A1 412/4885CYP1A2 956/4885 |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | GPR3 752/4885ALDH1A1 295/4885CYP1A2 313/4885 |
| US-20050187227-A1 | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition | DPP8, DPP4, DPP7 | GPR3 531/4885ALDH1A1 249/4885CYP1A2 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.